USPTO serial 88585560
BYONDIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 14, 2020
- Examiner
- MCCAULEY, BRENDAN D
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BYONDIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Synthon Biopharmaceuticals B.V
CM Nijmegen, NL
CM NIJMEGEN, NL
Synthon Biopharmaceuticals B.V
CM Nijmegen, NL
Synthon Biopharmaceuticals B.V
CM Nijmegen, NL
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
E. Anthony Figg
E. Anthony Figg ROTHWELL FIGG ERNST & MANBECK PC901 New York Avenue, NWSuite 900 EastWashington, DC 20001Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceutical preparations, substances and compositions, namely, antibacterial substances for medical purposes, medical diagnostic reagents in the nature of antibody-drug conjugates, immuno-oncology compounds in the nature of medicinal preparations for the treatment of infectious diseases and for use in oncology, and compounds for auto-immune diseases, namely, pharmaceutical preparations for the treatment of immune system related diseases and disorders; biopharmaceutical active substances, namely, diagnostic agents, preparations and substances for medical purposes in the nature of antibody-drug conjugates, immuno-oncology compounds, namely, pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders, and compounds for auto-immune diseases, namely, pharmaceutical preparations for the treatment of immune system related diseases and disorders; biological and biochemical drug and cultures for medical use, namely, biological preparations for the treatment of cancer, cultures of microorganisms for medical use, and biological tissue cultures for medical purposes; biopharmaceutical active substances, namely, nutritive substances for microorganism cultures; biopharmaceutical components and ingredients, namely, plant and herb extracts sold as components of medicated cosmetics; orthopedic articles, namely, bone repair paste for use in orthopedic surgery; all of the above excluding for the treatment of neuromuscular diseases and disorders | ACTIVE | — |
| 010 | Surgical and medical devices, apparatus and instruments, namely, surgical instruments and apparatus, surgical devices and instruments, surgical apparatus and instruments, medical instruments for cutting tissue, and medical instrument for performing biopsies, medical fluid injectors, injection device for pharmaceuticals, syringes for medical purposes, disposable syringes for medical purposes; orthopedic articles, namely, orthopedic walkers, orthopedic supports, orthopedic braces and orthopedic cushions; injection apparatus for medical purposes, namely, injection needles and injection instruments with needles | ACTIVE | — |
| 035 | Providing office functions relating to the registration of pharmaceutical preparations and components and pharmaceutical drugs; providing office functions relating to obtaining pharmaceutical registrations and compiling pharmaceutical registration files; business mediation of commercial transactions for others, mediation of contracts for the purchase and sale of products, and mediation of agreements all in the field of the purchase, sale and licensing of pharmaceutical registrations and pharmaceutical registration files | ACTIVE | — |
| 042 | Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of antibody-drug conjugates, immuno-oncology compounds and compounds for auto-immune diseases and scientific research related thereto; scientific and technological services relating to obtaining pharmaceutical registrations and compiling pharmaceutical registration files, namely, scientific research in the field of pharmaceuticals for pharmaceutical registration purposes; pharmaceutical research services and pharmaceutical research consultancy services; biomedical research services and biomedical research consultancy; medical research and medical research consultancy; scientific laboratory services in the fields of chemistry and biology, antibody-drug conjugates, immuno-oncology compounds and compounds for auto-immune diseases; scientific laboratory services; product development of pharmaceutical products and ingredients for pharmaceuticals; providing information relating to medical and scientific research in the field of pharmaceutical preparations; providing medical and scientific research information regarding the results of clinical trials for pharmaceutical preparations; quality control of products for others to determine conformity with certification standards; laboratory research, namely, scientific and medical research; laboratory analysis in the field of chemistry and biology as related to pharmaceuticals; product research for the pharmaceutical industry; design of pharmaceuticals for the pharmaceutical industry; product research and development for others; drug discovery services; testing in the context of quality control, namely, material testing and product testing; conducting clinical trials for others in the field of pharmaceutical preparations; quality control for others in the field of pharmaceutical preparations; providing information and data relating product research and developments in the pharmaceutical, biopharmaceutical and medical fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Synthon Biopharmaceuticals B.V
- Other trademarks owned by BYONDIS B.V.
- Other trademarks owned by Synthon Biopharmaceuticals B.V
- Other trademarks owned by Synthon Biopharmaceuticals B.V
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named BYONDIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 23, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 5, 2025 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Apr 14, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Nov 21, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 21, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 13, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 14, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 28, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 28, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 19, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 12, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 11, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 11, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 11, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 11, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 11, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 9, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 2, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 2, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 29, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 20, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Oct 31, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 25, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Sep 5, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 23, 2019 | NWAP | NEW APPLICATION ENTERED | — |